Published in final edited form as:

Int J Radiat Oncol Biol Phys. 2017 October 01; 99(2): 362–373. doi:10.1016/j.ijrobp.2017.04.014.

Stimulating innate immunity to enhance radiation therapy-induced tumor control

Jason R. Baird, PhD^{*,a}, Arta M. Monjazeb, MD PhD^{*,b,c}, Omid Shah, MD^d, Heather McGee, MD PhD^e, William J. Murphy, PhD^c, Marka R. Crittenden, MD PhD^{a,f}, and Michael J. Gough, PhD^{a,g}

^aEarle A. Chiles Research Institute, Providence Cancer Center, Portland OR

^bDepartment of Radiation Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA 95817

^cLaboratory of Cancer Immunology, UC Davis Comprehensive Cancer Center, Sacramento, CA 95817

^dDepartment of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, California 94305-5323

^eDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

^fThe Oregon Clinic, Portland, OR

Abstract

Novel ligands that target Toll-like receptors and other innate recognition pathways represent a potent strategy for modulating innate immunity to generate anti-tumor immunity. While many of the current clinically successful immunotherapies target adaptive T-cell responses, both pre-clinical and clinical studies suggest that adjuvants have the potential to enhance the scope and efficacy of cancer immunotherapy. Radiation may be a particularly good partner to combine with innate immune therapies, since it is a highly efficient means to kill cancer cells, but may fail to send the appropriate inflammatory signals needed to act as an efficient endogenous vaccine. This may explain why although radiation therapy is a highly used cancer treatment, true abscopal effects – regression of disease outside the field without additional systemic therapy – are extremely rare. This review focuses on efforts to combine innate immune stimuli as adjuvants with radiation, creating a distinct and complementary approach from T cell targeted therapies to enhance anti-tumor immunity.

^gContact author: Michael Gough PhD, Earle A. Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan St, Portland, OR 97213, Tel: 503-215-3928, Fax: 503-215-6841, michael.gough@providence.org.

*Authors contributed equally

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

radiation; adjuvant; innate; immunotherapy; TLR; STING; IFN; TNF

Introduction

Ionizing radiation has the ability to induce various types of cell death, including apoptosis, necrosis, necroptosis, and autophagy, which have been shown to have both immunosuppressive or immunogenic effects¹. Radiation directed to one tumor site can induce the regression of tumor(s) at other distant site(s), a phenomenon known as the abscopal effect. However, despite approximately 500,000 radiation treatments per year in the USA, Abuodeh *et al.* recently described that there have been only 21 cases of abscopal tumor regression of solid tumors reported in the literature over the past 45 years, excluding recent reports of radiation therapy combined with systemic immunotherapy². This suggests that radiation therapy alone does not generate clinically significant systemic immunity. Since radiation therapy remains an effective means to induce cell death and provide antigen to the immune system, we have to consider why radiation does not generate systemic immunity as a single agent.

Most of the recent studies that have validated radiation therapy as an effective partner for immunotherapy in preclinical and clinical settings have utilized immunotherapies that block T cell checkpoint regulatory molecules, such as *antagonistic* anti-CTLA4 and anti-PD1 antibodies that block *inhibitory* signals on T cells to unleash full T cell effector function^{3–8}, or *agonistic* antibodies that target 4-1BB and OX40, *costimulatory* molecules that are present for a short period after antigen stimulation. Ligation of these co-stimulatory molecules results in expansion of antigen-stimulated T cells^{9–14} including tumor-specific T cells and drive their differentiation into effector and memory T cells with anti-tumor potential^{15–17}. One of the classic tenets in immunology states that T cells require three signals in order to generate effective immunity. *Signal 1* comes from antigen bound to MHC class I or MHC class II signaling through the T cell receptor. *Signal 2* is a co-stimulatory signal (B7.1 and B7.2 on antigen presenting cells (APC) binding to CD28 on T cells), and *Signal 3* is a cytokine that helps shape the subsequent immune response. Thus, antigen without adjuvant fails to generate effective adaptive immunity because it provides signal 1 without signals 2 or 3 resulting in tolerance or anergy. While radiation provides dying cells as a source of antigen (Signal 1), we propose that radiation does not provide sufficient co-stimulation (signal 2) or cytokine release (signal 3) to efficiently activate the adaptive immune system. While cytokines are induced in tumors following radiation therapy, the poor efficacy of radiation alone as an endogenous vaccine is most clear when compared to strong exogenous vaccines: in preclinical experiments, our work has shown that the T cell response to antigens from dying cancer cells can be an order of magnitude lower than the response to antigens expressed in bacteria or viruses.

Dying cells can provide adjuvant in the form of DAMPs (danger associated molecular patterns) by expressing heat shock proteins^{18–20}, releasing HMGB1^{21,22} or translocating calreticulin²³, and lysis of tumor cells has been associated with the adjuvant activity of

IL-33²⁴ and uric acid^{25,26}. However, M2 polarized macrophages, the dominant myeloid cell in most tumor environments, respond to adjuvant by secreting cytokines such as VEGF, IL-10 and TGF β ^{27–29}, which are viewed as tumor supporting or immunosuppressive molecules. Moreover, irradiated cancer cells have been shown to drive undifferentiated macrophages towards M2 polarization^{27,30–32} despite the adjuvant content of irradiated cells. These macrophages limit the efficacy of radiation therapy in a range of mouse models^{33–37}, and preventing M2 polarization enhances radiation tumor control by radiation therapy^{27,38}. Taken together, these data suggest that the endogenous adjuvant activity of irradiated cancer cells is often insufficient to overcome the preexisting suppressive environment of the tumor and may even enhance the suppressive M2 macrophage environment. Since any immune response generated following tumor radiation very rarely influences tumors outside the treatment field², it is logical to increase the immunogenicity of radiation therapy via the exogenous delivery of adjuvant.

Toll-like receptors (TLR) are pattern recognition receptors capable of recognizing microbial products³⁹. Signaling through distinct TLR can share downstream pathways such as MyD88 and TRIF, but TLR expression varies across cell types (Figure 1). Therefore, the consequence of TLR ligation can vary according to the cell type and their differentiation^{40,41}. More recently characterized STING and RIG-I-like receptors have also been shown to trigger the release of key innate cytokines such as type I IFN and TNF α . This review will focus on the synergy between activation of innate immune receptors and radiation therapy.

TLR3

TLR3 is particularly expressed in DC and macrophage subsets (Figure 1) and mediates the host response to double stranded RNA in infectious agents⁴². Interestingly, the infected cell does not need to respond to the presence of double stranded RNA, but it is critical that dendritic cells express TLR3 in order to efficiently cross-present antigens from infected cells⁴³. This is applicable to our goal to generate adaptive immune priming following radiation therapy, as the CD8⁺ DC population is critical for cross-presentation of cell-associated antigens to generate T cell responses⁴⁴, and dying cells are efficiently tolerogenic without adjuvant^{45,46}. TLR3 is unusual amongst TLRs because it uses TRIF rather than MyD88 to signal^{41,47}.

The synthetic TLR3 ligand poly(I:C) has been used as a cancer immunotherapy for over 45 years. Intraperitoneal administration of poly(I:C) first showed clinical promise in treating a mouse model of melanoma⁴⁸. Poly(I:C) has been widely used in vaccines, providing adjuvant signals to a range of antigen sources, including free peptides and tumor-derived apoptotic cells (reviewed in⁴⁹). Early studies with poly(I:C) showed limited benefit due to its short half-life⁵⁰, but a modified, degradation-resistant poly(ICLC)⁵¹ has shown increased cytokine induction, but also has produced increased toxicity in patients (reviewed in^{49,50}). Poly(I:C) can also activate RIG-I-like receptors when poly(I:C) gains access to the cytosol. For this reason, as will be discussed below, some of the activities formerly ascribed to TLR3 are also dependent on RIG-I like receptors such as MDA5^{52–54}.

A few studies have examined poly(ICLC) in combination with radiation therapy. A phase II study of intramuscular poly(ICLC) and fractionated radiation following surgery in patients with glioblastoma showed improved survival compared to historical controls⁵⁵. Similarly, a phase II study combining fractionated chemoradiation with intramuscular poly(ICLC) reported that the combination was well tolerated and that median survival was longer than prior studies with chemoradiation alone⁵⁶. However, thus far there are no reports demonstrating efficacy of the combination of radiation therapy with poly(ICLC) in randomized clinical trials.

TLR4

TLR4 is expressed in neutrophils and macrophages (Figure 1), and ligation of TLR4 by lipopolysaccharide (LPS) or endogenous damage associated molecular patterns (DAMPs) such as hyaluronan, heat shock proteins (HSP), and HMGB1⁴¹ results in signaling through MyD88 dependent and independent pathways^{57,58}. Many of these factors can be released after radiotherapy and pre-clinical studies have demonstrated the importance of this endogenous TLR signaling to the success of radiotherapy. Apetoh *et al.* demonstrated that the release of HMGB1, resulting from radiotherapy- or chemotherapy -induced cell death, triggered TLR4, which in turn increased the processing and presentation of tumor antigens²¹. This process of “immunogenic cell death” was found to be critical to the anti-tumor effects of cytotoxic therapy because TLR4 knockout or blocking HMGB1 drastically abrogated the efficacy of therapy. Additionally, endogenous activation of TLR by microbiota may also play a role in the anti-tumor effects of radiotherapy since translocation of gut microbiota and subsequent TLR4 activation is critical to the efficacy of total body irradiation and adoptive transfer in mouse models⁵⁹.

Early experiments demonstrating the efficacy of LPS as a therapy were performed in the late 1960s, and these early experiments recognized a tight balance between toxicity and efficacy⁶⁰. A range of purified LPS preparations have been tested in clinical studies for cancer (reviewed in⁶¹) with moderate efficacy, however, the systemic toxicities of LPS are often due to the systemic consequences of IL-1 and TNF α production. Intratumoral administration of LPS has been shown to permit complete regression of tumors⁶². However, few studies have tested the addition of exogenous TLR4 ligands as partners for radiation therapy. BCG can be used to trigger TLR4 and increase the radiosensitivity of HCT-116 colon carcinoma cells by increasing autophagy⁶³; however, many cancer cells cannot directly respond to TLR4 and as with other TLR ligands, it is more important that the stromal and immune cells can respond to the TLR ligand than the cancer cell⁶⁴.

While LPS can induce potent pro-inflammatory responses from macrophages in particular contexts, as discussed above LPS treatment of tumor macrophages following radiation therapy results in secretion of cytokines that are anti-inflammatory and support tumor growth and tissue repair^{27–29,65}. These data suggest that while LPS is a potent immune adjuvant, and while endogenous TLR4 adjuvants contribute to tumor control following radiation therapy, TLR4 ligation can have anti-inflammatory as well as proinflammatory effects, depending on the differentiation of the responding cells.

TLR7

TLR7 is highly expressed in monocyte and macrophage lineages (Figure 1), and the synthetic TLR7 ligand Imiquimod has been used successfully as an immunotherapy for dermatological malignancies and pre-malignancies⁶⁶. Imiquimod has been shown to have direct cytotoxic effects on squamous cell carcinoma cell lines *in vitro*⁶⁷, but when administered *in vivo*, the control of squamous cells is not direct and is dependent on the cytokines and inflammation generated by immune cells^{68–71}. Topical administration of Imiquimod can alter the immune environment of skin metastases of breast cancer with some evidence of local tumor response⁷². In a preclinical mammary carcinoma model, topical administration of Imiquimod changed the immune environment in underlying subcutaneous tumors, and led to growth delay of both the primary treated tumor and a distant tumor⁷⁰. In addition, delivery of radiation ($8\text{Gy} \times 3$) significantly increased the number of complete local responses. Regression of distant unirradiated tumors was also observed if they were also treated with topical Imiquimod⁷⁰.

However, the solubility profile of Imiquimod has limited its clinical application. There are TLR7 ligands that can be applied systemically⁷³. Dovedi *et al.* demonstrated that systemic application of a novel TLR7 ligands synergized with RT for control of preclinical B and T cell lymphoma models⁷⁴. This effect was entirely dependent on CD8 T cells and resulted in antigen-specific T cell immunity. Following from this work, Adlard *et al.* demonstrated that systemically delivered TLR7 agonist significantly improved survival in combination with RT in preclinical models of solid tumors⁷⁵ while systemic delivery without RT did not impact tumor growth or progression. Improved survival was observed both with a fractionated dose of $2\text{Gy} \times 5$ and a single fraction of 15Gy .⁷⁵ By contrast, in the T cell lymphoma model, systemic administration of the TLR7 agonist was more effective with fractionated radiation ($2\text{Gy} \times 5$) than with a single fraction of 10Gy ⁷⁴. These data show that novel TLR7 ligands have significant therapeutic potential to treat cancer, particularly in conjunction with radiation therapy.

TLR9

TLR9 has a broad expression profile, in B cells, dendritic cells, macrophages and monocytes, and signals primarily through MyD88- dependent pathways. TLR9 recognizes unmethylated CpG oligonucleotide sequences that are present in microbial DNA but not mammalian DNA, as well as endogenous DAMPs including chromatinDNA complexes and ribonucleoproteins^{4176,77}. Synthetic CpGs that activate TLR9 have been demonstrated to be superior to bacterially derived products in tumor therapy⁷⁸. A side-by-side comparison demonstrated that CpG oligonucleotides were the most effective single-agent cancer therapeutic compared to other TLR ligands⁶⁴. In general, CpGs induce the activation and maturation of DCs resulting in secretion of type I interferon and up-regulation of co-stimulatory molecules such as CD80 and CD86⁷⁹, leading to the activation of natural killer (NK) cells⁷⁹ and the expansion of cytotoxic T lymphocytes. CpGs also enhance the differentiation of B cells into antibody-secreting plasma cells which can eradicate tumor cells through antibody dependent cellular cytotoxicity^{80–82}.

A number of studies have shown that TLR9 agonists have anti-tumor effects in murine models when initiated while tumors are small^{76,83–90}. Direct intratumoral or local injection of CpG appears to be more effective and less toxic than systemic administration⁹¹. Certain cancers can be refractory to single agent CpG due to low expression of MHC-I and the abundant expression of immunosuppressive TGFβ⁹². Overall, the most potent effects of CpG therapy are seen when used in combinatorial strategies. CpGs have been tested in combination with ionizing radiotherapy using *in vitro* models, animal models and in clinical trials^{91–101} and found to be superior in anti-tumor activity compared to either modality alone. Initial studies performed by Milas and colleagues demonstrated significant local synergy for single fraction and fractionated radiotherapy regimens in combination with CpG^{95,96}. In a mouse fibrosarcoma model they demonstrate that the TCD50 for fractionated radiotherapy is reduced almost 4-fold (from 83.1 Gy to 23 Gy) when combined with CpG. The local synergy of radiotherapy and CpG was independently verified by a second group in a glioma model⁹⁷. Although the exact mechanism of CpG-mediated radiosensitization is not known, studies have suggested that CpG increases both mTOR activation and autophagy¹⁰², decreases expression of Oct-4- mediated renewal¹⁰³, and increases NF-κB signaling and nitric oxide production⁹⁴.

In vivo, the efficacy of radiation in combination with CpG caused both improved local control and the generation of systemic immunity. Guha and colleagues demonstrated synergistic effects of CpG and radiation against both local irradiated tumor and systemic lung metastases in a 3LL tumor model⁹⁸. This correlated with an increase in a humoral anti-tumor immune response and increased activation of dendritic cells. Clinical studies combining intralesional CpG with local radiotherapy have confirmed the safety and efficacy of this combinatorial approach in humans. A series of clinical trials by Levy and colleagues in low-grade lymphomas and demonstrated that this combinatorial approach is capable of inducing objective responses outside of the irradiated and injected lesion in about 20% of patients and disease stability in about another 20% of patients with heavily pretreated systemic⁹¹ or cutaneous lymphoma⁹⁹. Many of the responses were durable and lasted for months or years.

Despite the potent immune stimulation of TLRs, studies using CpG as a therapeutic have highlighted that the increased immune effect may be a doubled edged sword. TLR activation combined with radiotherapy can generate immune responses, but as acute inflammation becomes chronic, immune suppression will ensue. Thus, chronic endogenous TLR9 signaling instigated by radiotherapy induces chronic inflammation and increases tumor recurrence¹⁰⁴. In the clinical studies of radiotherapy combined with CpG described above, patients whose tumors induced immunosuppressive regulatory Tregs responded poorly to therapy and had a poor prognosis¹⁰⁷. Radiotherapy combined with CpG was found to upregulate indoleamine 2,3-dioxygenase (IDO) expression, which was termed “rebound immune suppression”¹⁰⁵. This upregulation of IDO occurred in response to the inflammation induced by radiotherapy and TLR activation, generating an immune suppression that included Tregs. The addition of IDO blockade reversed immune suppression and significantly improved the local and systemic efficacy of radiotherapy combined with CpG in murine models as well as companion canines with late stage metastatic spontaneous melanomas or sarcomas¹⁰⁵. As discussed below, this rebound immune suppression may be a

common feature of potent IFN-inducers^{106–108}, thus a triple therapy approach which includes blockade of immune suppression to achieve maximal efficacy may be required to increase the clinical impact of these combinatorial approaches.

RIG-I like receptors

RIG-I, MDA5 and LGP2 are cytoplasmic sensors of viral RNA and signal through MAVS to activate type I IFN responses in infected cells. RIG-I recognizes dsRNA containing 5' triphosphates and biphosphates¹⁰⁹, which are present in the nucleus of cells early following transcription, but are removed before entry into the cytoplasm. During infection, the entry of unmodified RNA into the cytoplasm, triggers these sensors and activates the production of type I IFN¹¹⁰. RIG-I¹¹¹ and LGP2¹¹², but not MDA5,¹¹³ also can detect endogenous nuclear material that has translocated to the cytoplasm following radiation therapy. Irradiated cells activate type I IFN production in a RIG-I dependent manner and mice lacking RIG-I were protected against gastrointestinal epithelial cell death following total body radiation¹¹¹. By contrast, LGP2 has an opposite effect and suppresses type I IFN induced by radiation therapy¹¹².

While we now know that specific sequences activate RIG-I like receptors, these sequences are present in poly(I:C), which was initially thought to be exclusively a TLR3 ligand. Knockout studies using a range of synthetic ligands on dendritic cells demonstrated that MDA5 activates type I IFN responses to poly(I:C) but RIG-I does not⁵³. The receptor that recognizes poly(I:C) can be influenced by the route of administration – for example, RIG-I like receptors may require that the ligand access the cytoplasm. However, the cell types and pattern of receptor expression also will influence the use of these various ligands. Thus, conventional dendritic cells rely on RIG-I like receptors while plasmacytoid DCs rely on TLR3 binding to the same ligand⁵⁴. Therefore, many of the studies discussed above that used poly(I:C) as a therapeutic agent may have activated a TLR3 pathway, a RIG-I like receptor pathway, or both.

Although differential activation of the two receptors (RIG-I and TLR3) may lead to different outcomes, it seems that the presence of both pathways leads to maximal response to poly(I:C). In the TRAMP murine model of prostate adenocarcinoma, poly(I:C) administered systemically resulted in complete control of tumor growth, and although much of this was lost in TLR3 knockout mice, some activity remained¹¹⁴. The authors attribute this to direct activity of the systemic poly(I:C) on the cancer cells, but this could also represent the activity of poly(I:C) on RIG-I like receptors. Similarly, in a model of poly(I:C)-induced lung pathology, TLR3 knockout mice exhibited similar responses with a reduced magnitude, and this may represent the activity of RIG-I like receptors¹¹⁵. Interestingly, a non-hematopoietic stromal MDA5 response was shown to be required for the full efficacy of poly(I:C) as a vaccine adjuvant⁵², so it is possible that local inflammation driven by stromal cells is critical to support antigen-specific responses. Further studies will be necessary to determine the relative value of selective targeting of TLR3 and RIG-I like receptors, but at the moment, the data suggests that the dual response to poly(I:C) is advantageous in cancer therapy.

STING

Recently, there has been a surge of interest in STING (STimulator of INterferon Genes) for its role as a cytosolic sensor of DNA. Initially, the functions carried out by STING were attributed to TLR9, which can recognize CpG DNA and drive type I IFN responses to microbial DNA. However, double stranded DNA also activated type I IFN responses in cells lacking TLR signaling pathways and RIG-I, and this suggested that there was an unrecognized DNA-sensing mechanism that remained to be discovered¹¹⁶. The STING-dependent cytosolic DNA sensing pathway was discovered by two independent groups using a cDNA screen to identify proteins that induced type I IFN or IRF^{117,118}. STING is widely expressed both among hematopoietic cells (Figure 1) and non-hematopoietic cells including cancer cells¹¹⁹.

The STING pathway likely evolved as an intracellular sensor of pathogen DNA such as bacterial cyclic-di-nucleotides (CDN)^{120,121}. Mice deficient in STING also show impaired clearance of DNA viruses due to impaired generation of a type I IFN-driven immune response¹²². However, as has been described for RIG-I like receptors and unmodified RNA, STING has also been shown to sense the presence of endogenous DNA introduced into the cytoplasm¹²³. These data suggest that STING may be able to sense endogenous DNA released within irradiated cancer cells; however Deng *et al.* demonstrated that the major mechanism of STING activation following radiation of cancer cells resulted following with cross-presentation of cell-associated antigens to dendritic cells¹²⁴. In these experiments, expression of STING by the cancer cells was not required for radiation therapy-induced tumor cure, which instead was entirely dependent on STING expression in host dendritic cells¹²⁴. In highly immunogenic tumors, host expression of STING is necessary for spontaneous tumor regression¹²⁵. In these models, cancer cells killed by a range of methods including radiation and freeze thaw were unable to active type I IFN activation in dendritic cells; however, tumor-derived DNA transfected into the cytoplasm of DC was a potent STING-mediated activator of type I IFN production. Although it is unclear how tumor DNA is transferred to the DC cytoplasm in vivo, mice deficient in STING were unable to generate type I IFN following tumor challenge, failed to generate effective anti-tumor immunity, and were less responsive to immunotherapy¹²⁵. These data suggest that the inflammatory component of cross presentation at tumor challenge was critical to generate T cell responses to tumor antigens. In a different model system using less immunogenic tumors, STING activation in the host following tumor challenge was shown to *inhibit* endogenous anti-tumor immunity¹⁰⁶. The mechanism was again via induction of type I IFN but this time also resulted in subsequent induction of the immune suppressive enzyme IDO, resulting in increased tumor growth rates. However, other studies have not found a change in tumor growth rate in wild type versus STING knockout animals that are otherwise untreated^{119,124,126}. It is possible that some feature of the cultured cancer cells, their preparation, or their route of delivery at transfer differentially affects the likelihood and consequence of STING activation in the host.

Since CDN activation of STING results in potent induction of type I IFN, CDN have been shown to be effective vaccine adjuvants^{127,128}. In addition, direct injection of CDN into tumors has been shown to cause dramatic regression in a range of tumor models¹²⁶.

Interestingly, STING was recently found to be the gene activated by DMXAA¹²⁹, which is a highly active vascular disrupting agent resulting in hemorrhagic necrosis of tumors, though with variable results depending on the tumor model¹³⁰. DMXAA activates mouse, but not human STING¹³¹, potentially explaining the failure in clinical translation of DMXAA. Novel CDN have been engineered for increased potency against mouse STING and human STING isoforms^{126,128}, and novel small molecule agonists of the STING pathway have been identified¹³². While cancer cells can express STING¹¹⁹, tumor therapy with CDN is ineffective in mice lacking STING¹²⁶, indicating that host STING is critical for anti-tumor activity. This also explains why DMXAA was able to cause vascular disruption in xenografts of human tumors in immunodeficient mice¹³³, since cancer cell expression of STING was not relevant to treatment outcome. These data from immunodeficient mice also suggest that the anti-tumor efficacy of STING ligands is not necessarily dependent on functional adaptive immunity.

Both DMXAA and CDN have shown efficacy in combination with radiation therapy. DMXAA administered systemically resulted in increased tumor control by RT in a radiation and DMXAA dose-dependent manner^{134,135}, and with fractionated radiation¹³⁵. In the MC38 colorectal model that was not affected by intratumoral injection of CDN, the combination of CDN and RT resulted in significantly increased tumor control over RT alone¹²⁴. Similarly, in a range of tumor models and mouse strains the combination of CDN and RT was shown to result in therapeutic synergy¹¹⁹. These effects were dependent on STING expression in the host, and resulted in TNF α -induced hemorrhagic necrosis in the tumor¹¹⁹. In these models, radiation therapy was necessary to produce CD8 T cell immunity and control distant disease, but optimal tumor control was dependent on both an early T cell independent, TNF α -dependent rapid tumor regression and a later, CD8 T cell dependent mechanism that contributed to the durable response of treated tumors¹¹⁹. These data demonstrate that STING ligands create synergy with radiation therapy for immune-mediated control of cancer.

Type I IFN

Type I IFN is induced downstream of many of the innate immune activators mentioned above. Type I IFN includes IFN α and IFN β , which signal through the receptors IFNAR1 and IFNAR2^{136,137} (Figure 1). This contrasts with type II IFN, or IFN γ , which signals through IFNGR1 and IFNGR2, and type III IFN, that includes IFN-lambda and IL-10^{136,137} and signals through two α subunits and two β subunits. The ability to produce and respond to type I IFN is shared by almost all cell types, though plasmacytoid dendritic cells are able to secrete higher levels of type I IFN than any other cell type^{130,139}. Activation of IFN receptors leads to a multifaceted response. They generate an innate anti-viral and anti-microbial state among infected and bystander cells, limiting the spread of pathogens, and also promote NK cell function and antigen presentation by dendritic cells to activate T cells (reviewed in^{136,137}). However, type I IFN can also induce immune suppressive mechanisms, such as induction of the immune suppressive enzyme IDO¹⁰⁶. IDO tolerizes adaptive immune responses¹⁴⁰ and can be harnessed to treat T cell-mediated autoimmunity¹⁴¹. Thus, as with many immune stimuli, there is a contextual and dose-related consequence of type I IFN activation *in vivo*. As has been shown for IFN γ , type I IFNs also result in upregulation

of PDL1 by stromal cells and cancer cells¹⁴², and therefore a role in feedback regulation of adaptive immunity.

The expression of type I IFN and IFN-responsive genes have been correlated with favorable outcome in cancer patients. A type I IFN gene signature is induced by chemotherapy and radiation therapy in some patients. This type I IFN gene signature is associated with improved outcome following neoadjuvant chemotherapy in breast cancer patients¹¹¹. However, this interferon signature is expressed in a broad array of cancer cell lines, and predicts a poor response to chemotherapy and radiation therapy in patients with breast cancer¹⁴³ and glioblastoma¹⁴⁴. In preclinical models, the efficacy of radiation therapy was shown to be dependent on induction of type I IFN in murine tumor models¹⁴⁵. Using bone marrow chimeras it was demonstrated that a functional response to radiation was dependent on IFNAR1 expression in hematopoietic cells, but not T cells, and IFNAR1 knockout mice lacked functional cross-presentation of tumor antigens by dendritic cells¹⁴⁵. Type I IFN has been shown to be required for priming of T cell responses and recruitment of tumor-specific T cells to treated sites¹⁴⁶.

Type I IFN has been well studied as an adjuvant therapy for melanoma, resulting in improved recurrence-free survival^{147,140}, but no improvement on overall survival¹⁴⁹. Type I IFN has long been known to radiosensitize cancer cells *in vitro*¹⁵⁰, and some of the earliest studies of immunotherapy combined with radiation therapy involved local or systemic application of type I IFN. This has shown mixed signs of efficacy in a range of tumor types, but toxicities have limited application of this therapy. Preclinical studies in pancreatic cancer have shown improved outcome with type I IFN and chemotherapy in pancreatic cancer^{151,152}, and early phase studies suggested improved outcome in patients receiving type I IFN along with adjuvant chemoradiation¹⁵³. Multicenter studies suggested an improved outcome; however, they also resulted in grade III or IV toxicity in 90% of patients¹⁵⁴. A multicenter, randomized phase III trial of adjuvant chemoradiation plus type I IFN did not demonstrate a benefit of combinatorial therapy versus 5-FU alone and resulted in grade III toxicity in 85% of patients¹⁵⁵. These data indicate that systemic delivery of type I IFN is significantly limited by toxicities and does not provide a favorable therapeutic ratio.

To minimize systemic consequences, type I IFN can be injected in the local tumor environment to generate tumor control¹⁵⁶, and intratumoral injection of an adenoviral vector expressing murine IFN β can produce T cell-dependent control of a murine melanoma model¹⁴⁵. Alternatively, IFN can be engineered to accumulate in the vicinity of cancer cells using immune-conjugates. Anti-CD20 coupled to type I IFN was shown to be an effective therapy against lymphoma¹⁵⁷ but hematological malignancies therapies require direct action of type I IFN on the cancer cells¹⁵⁷. An anti-EGFR-IFN β conjugate was effective against murine solid tumors expressing human EGFR, and in these models tumor clearance was dependent on functional adaptive immunity¹⁵⁸. Further refinement of type I IFN delivery systems could potentially expand the use of this cytokine for cancer therapy.

TNF α

TNF α was identified as the factor induced by Coley's toxins responsible for necrosis of tumors^{159,160}. Sufficient TNF α can produce rapid hemorrhagic necrosis as a result of vascular endothelia activation and death. In addition, TNF α can induce cancer cell apoptosis. As described above, TNF α -mediated hemorrhagic necrosis of tumors has been described following administration of STING ligands, LPS, poly(I:C) and CpG^{119,130,161,162}. However, the lower levels of endogenous TNF α produced by macrophages in the tumor environment has been shown to promote tumor regrowth following radiation therapy¹⁶³. In addition, TNF α produced downstream of pattern recognition receptor ligation is the main factor contributing to systemic shock^{164,165} and can be causative of other toxicities. For example, pulmonary administration of CpG resulted in TLR9-dependent alveolitis and pneumonitis in mice, and this toxicity was lost in TNF α knockout mice¹⁶⁶.

To minimize systemic toxicity, TNF α has been engineered into an adenoviral vector with expression controlled by a radiation-responsive promoter (reviewed in¹⁶⁷). This promoter has been optimized to generate up to a 3-fold induction of gene expression following radiation therapy¹⁶⁸ and this construct has been successfully used to induce vascular thrombosis in human tumor xenografts in immunodeficient mice¹⁶⁹. Similarly, cancer cells modified to express TNF α constitutively or in response to radiation therapy have been shown to improve the clinical response to implanted radioactive seeds¹⁷⁰. In immunocompetent mice, gene delivery of TNF α using an adenoviral vector resulted in improved tumor control following a single fraction of 20Gy, with a large portion of the effect due to CD8 T cells¹⁷¹. These data suggest that responses incorporate both a direct effect of TNF α on vascular cells, and a CD8-mediated adaptive immune response.

In the clinic, radiation-inducible TNF α gene therapy showed evidence of efficacy in preclinical and Phase II studies (reviewed in¹⁶⁷); however, randomized phase III studies in locally advanced pancreatic cancer failed to show efficacy¹⁷². These data suggest that while TNF α is an extremely important effector cytokine that can have dramatic effects on tumors, it is very difficult to target TNF α clinically because of its pleiotrophic effects within the immune system, and subsequent toxicities.

Conclusions

Though cancer cells contain endogenous adjuvants with the potential to stimulate innate sensors, radiation therapy is not an effective stimulator of systemic immunity without the addition of immunotherapy². It is possible that irradiated cells are only able to generate type I IFN responses in some patients, explaining variation in outcome according to the IFN gene signature^{143,144}. This may be due to genetic variation in the endogenous DNA sensors, as has been proposed for TLR4²¹, or due to the particular immune tumor environment. Nevertheless, the variable response presents an important opportunity to deliver the appropriate exogenous adjuvants to deliver missing signals and tap into the potential of radiation therapy as a patient-specific endogenous cancer vaccine (Figure 2).

When using adjuvants in addition to RT, we must dedicate efforts to learning how to best balance efficacy and toxicity. In addition, we must address the problem of local versus systemic delivery. Local delivery can maximize local tumor control while minimizing systemic toxicity, but this may also limit its clinical application. In addition, we must always consider how these therapies have the potential to interfere/suppress the adaptive immune response. As we have discussed, over-activation of inflammatory mechanisms by adjuvants can lead to adaptive immune suppression^{140,141}, requiring additional intervention such as inhibition of IDO¹⁰⁵. Adaptive immunity requires a critical sequence of signals and any deviation in the appropriate timing and degree of inflammation has the potential to limit antigen-specific immunity¹⁷³. The appropriate timing of adjuvant delivery in relation to radiation needs to be determined in order to ensure the success of this approach¹⁷⁴. While adjuvant might be the oldest cancer immunotherapy, the therapeutic potential of adjuvant remains to be fully exploited.

Acknowledgments

This work was supported by an American Cancer Society Postdoctoral Fellowship award (JRB), NCI R01 CA182311 (MJG), NCI R01 CA208644 (MRC), NIAID R21AI126151 (MRC), and NCI R03 CA198208 (MRC).

References

1. Honscheid P, Datta K, Muders MH. Autophagy: detection, regulation and its role in cancer and therapy response. *International journal of radiation biology*. 2014; 90:628–635. [PubMed: 24678799]
2. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. *Curr Probl Cancer*. 2015
3. Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015
4. Belcaid Z, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. *PloS one*. 2014; 9:e101764. [PubMed: 25013914]
5. Demaria S, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2005; 11:728–734. [PubMed: 15701862]
6. Sharabi AB, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1 Mediated Anti-Tumor Immune Responses via Cross-Presentation of Tumor Antigen. *Cancer Immunol Res*. 2014
7. Deng L, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *The Journal of clinical investigation*. 2014; 124:687–695. [PubMed: 24382348]
8. Zeng J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. *International journal of radiation oncology, biology, physics*. 2013; 86:343–349.
9. Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated costimulation in T-cell activation and survival. *Crit Rev Immunol*. 2009; 29:187–201. [PubMed: 19538134]
10. Ruby CE, Redmond WL, Haley D, Weinberg AD. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. *Eur J Immunol*. 2007; 37:157–166. [PubMed: 17183611]
11. Evans DE, Prell RA, Thalhoffer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. *Journal of immunology*. 2001; 167:6804–6811.

12. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. *Journal of immunology*. 2002; 168:4897–4906.
13. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. *Eur J Immunol*. 2000; 30:392–402. [PubMed: 10671194]
14. Vinay DS, Kwon BS. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells. *Cell Immunol*. 1999; 192:63–71. [PubMed: 10066348]
15. Melero I, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. *Nature medicine*. 1997; 3:682–685.
16. Weinberg AD, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. *Journal of immunology*. 2000; 164:2160–2169.
17. Gough MJ, et al. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. *Cancer Res*. 2008; 68:5206–5215. [PubMed: 18593921]
18. Gough MJ, et al. Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. *Gene Ther*. 2004; 11:1099–1104. [PubMed: 15103319]
19. Daniels GA, et al. A simple method to cure established tumors by inflammatory killing of normal cells. *Nat Biotechnol*. 2004; 22:1125–1132. [PubMed: 15300260]
20. Todryk S, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. *Journal of immunology*. 1999; 163:1398–1408.
21. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. *Nature medicine*. 2007; 13:1050–1059.
22. Telusma G, et al. Dendritic cell activating peptides induce distinct cytokine profiles. *Int Immunol*. 2006; 18:1563–1573. [PubMed: 16966494]
23. Obeid M, et al. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. *Cancer Res*. 2007; 67:7941–7944. [PubMed: 17804698]
24. Luthi AU, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. *Immunity*. 2009; 31:84–98. [PubMed: 19559631]
25. Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. *The Journal of clinical investigation*. 2010; 120:1939–1949. [PubMed: 20501947]
26. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature*. 2003; 425:516–521. [PubMed: 14520412]
27. Crittenden MR, et al. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. *PloS one*. 2012; 7:e39295. [PubMed: 22761754]
28. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol*. 2002; 23:549–555. [PubMed: 12401408]
29. Saccani A, et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. *Cancer Res*. 2006; 66:11432–11440. [PubMed: 17145890]
30. Golpon HA, et al. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. *Faseb J*. 2004; 18:1716–1718. [PubMed: 15345697]
31. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. *The Journal of clinical investigation*. 2002; 109:41–50. [PubMed: 11781349]
32. Fadok VA, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. *The Journal of clinical investigation*. 1998; 101:890–898. [PubMed: 9466984]
33. Kozin SV, et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. *Cancer Res*. 2010; 70:5679–5685. [PubMed: 20631066]

34. Ahn GO, et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107:8363–8368. [PubMed: 20404138]
35. Shiao SL, et al. TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. *Cancer Immunol Res*. 2015
36. Xu J, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. *Cancer Res*. 2013; 73:2782–2794. [PubMed: 23418320]
37. Stafford JH, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. *Neuro-oncology*. 2015
38. Crittenden MR, et al. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. *Oncotarget*. 2016
39. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science*. 1998; 282:2085–2088. [PubMed: 9851930]
40. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. *Annu Rev Immunol*. 2015; 33:257–290. [PubMed: 25581309]
41. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nature immunology*. 2010; 11:373–384. [PubMed: 20404851]
42. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of doublestranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. *Nature*. 2001; 413:732–738. [PubMed: 11607032]
43. Schulz O, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. *Nature*. 2005; 433:887–892. [PubMed: 15711573]
44. Iyoda T, et al. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. *The Journal of experimental medicine*. 2002; 195:1289–1302. [PubMed: 12021309]
45. Belz GT, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. *The Journal of experimental medicine*. 2002; 196:1099–1104. [PubMed: 12391021]
46. Liu K, et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. *The Journal of experimental medicine*. 2002; 196:1091–1097. [PubMed: 12391020]
47. Yamamoto M, et al. Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway. *Science*. 2003; 301:640. [PubMed: 12855817]
48. Bart RS, Kopf AW, Silagi S. Inhibition of the Growth of Murine Malignant Melanoma by Polyinosinic-Polycytidylic Acid. *Journal of Investigative Dermatology*. 1971; 56:33–38. [PubMed: 5556497]
49. Ammi R, et al. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. *Pharmacol Ther*. 2015; 146:120–131. [PubMed: 25281915]
50. Levine AS, Sivulich M, Wiernik PH, Levy HB. Initial Clinical Trials in Cancer Patients of Polyriboninosinic-Polyribocytidylic Acid Stabilized with Poly-L-lysine, in Carboxymethylcellulose [Poly(ICLC)], a Highly Effective Interferon Inducer. *Cancer research*. 1979; 39:1645–1650. [PubMed: 371793]
51. Levy HB, et al. A Modified Polyriboninosinic-Polyribocytidylic Acid Complex That Induces Interferon in Primates. *Journal of Infectious Diseases*. 1975; 132:434–439. [PubMed: 810520]
52. Wang Y, Cella M, Gilfillan S, Colonna M. Cutting edge: polyinosinic: polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. *Journal of immunology*. 2010; 184:2751–2755.
53. Kato H, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature*. 2006; 441:101–105. [PubMed: 16625202]
54. Kato H, et al. Cell type-specific involvement of RIG-I in antiviral response. *Immunity*. 2005; 23:19–28. [PubMed: 16039576]
55. Butowski N, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). *Journal of neuro-oncology*. 2009; 91:175–182. [PubMed: 18797818]

56. Rosenfeld MR, et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. *Neuro-oncology*. 2010; 12:1071–1077. [PubMed: 20615924]
57. Kawai T, et al. Lipopolysaccharide Stimulates the MyD88-Independent Pathway and Results in Activation of IFN-Regulatory Factor 3 and the Expression of a Subset of Lipopolysaccharide-Inducible Genes. *The Journal of Immunology*. 2001; 167:5887–5894. [PubMed: 11698465]
58. Yamamoto M, et al. Cutting Edge: A Novel Toll/IL-1 Receptor Domain-Containing Adapter That Preferentially Activates the IFN- Promoter in the TollLike Receptor Signaling. *The Journal of Immunology*. 2002; 169:6668–6672. [PubMed: 12471095]
59. Paulos CM, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *The Journal of clinical investigation*. 2007; 117:2197–2204. [PubMed: 17657310]
60. Mizuno D, Yoshioka O, Akamatsu M, Kataoka T. Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide. *Cancer Res*. 1968; 28:1531–1537. [PubMed: 5673568]
61. Galluzzi L, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. *Oncoimmunology*. 2012; 1:699–716. [PubMed: 22934262]
62. Chicoine MR, Won EK, Zahner MC. Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. *Neurosurgery*. 2001; 48:607–614. discussion 614–605. [PubMed: 11270552]
63. Yuk JM, et al. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. *Autophagy*. 2010; 6:46–60. [PubMed: 19901560]
64. Grauer OM, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. *Journal of immunology*. 2008; 181:6720–6729.
65. Lacave-Lapalun JV, Benderitter M, Linard C. Flagellin or lipopolysaccharide treatment modified macrophage populations after colorectal radiation of rats. *The Journal of pharmacology and experimental therapeutics*. 2013; 346:75–85. [PubMed: 23596059]
66. Huang SJ, et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. *The Journal of investigative dermatology*. 2009; 129:2676–2685. [PubMed: 19516264]
67. Schon M, et al. Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod. *JNCI Journal of the National Cancer Institute*. 2003; 95:1138–1149. [PubMed: 12902443]
68. Hemmi H, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. *Nature immunology*. 2002; 3:196–200. [PubMed: 11812998]
69. Gibson SJ, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. *J Interferon Cytokine Res*. 1995; 15:537–545. [PubMed: 7553223]
70. Dewan MZ, et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2012; 18:6668–6678. [PubMed: 23048078]
71. Ulrich C, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. *The British journal of dermatology*. 2007; 157(Suppl 2):25–31. [PubMed: 18067628]
72. Adams S, et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2012; 18:6748–6757. [PubMed: 22767669]
73. Dudek AZ, et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2007; 13:7119–7125. [PubMed: 18056192]

74. Dovedi SJ, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. *Blood*. 2013; 121:251–259. [PubMed: 23086756]
75. Adlard AL, et al. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. *International journal of cancer. Journal international du cancer*. 2014; 135:820–829. [PubMed: 24390981]
76. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature*. 1995; 374:546–549. [PubMed: 7700380]
77. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. *Nature*. 2000; 408:740–745. [PubMed: 11130078]
78. Rayburn ER, Wang W, Zhang R, Wang H. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. *Int J Oncol*. 2007; 30:1511–1519. [PubMed: 17487373]
79. Chaudhry UI, et al. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. *Cancer Res*. 2006; 66:10497–10504. [PubMed: 17079471]
80. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. *Nat Rev Drug Discov*. 2006; 5:471–484. [PubMed: 16763660]
81. Aurisicchio L, et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2009; 15:1575–1584. [PubMed: 19240169]
82. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. *Blood*. 2008; 112:2205–2213. [PubMed: 18591383]
83. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2003; 9:2693–2700. [PubMed: 12855649]
84. Ballas ZK, et al. Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs. *The Journal of Immunology*. 2001; 167:4878–4886. [PubMed: 11673492]
85. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. *Blood*. 2001; 98:1217. [PubMed: 11493473]
86. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *The Journal of experimental medicine*. 1997; 186:1623–1631. [PubMed: 9362523]
87. Heckelsmiller K, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. *Journal of immunology*. 2002; 169:3892–3899.
88. Kawarada Y, et al. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. *Journal of immunology*. 2001; 167:5247–5253.
89. Lonsdorf AS, et al. Intratumor CpG-Oligodeoxynucleotide Injection Induces Protective Antitumor T Cell Immunity. *The Journal of Immunology*. 2003; 171:3941–3946. [PubMed: 14530311]
90. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2003; 9:3105–3114. [PubMed: 12912962]
91. Brody JD, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2010; 28:4324–4332. [PubMed: 20697067]
92. Chamoto K, et al. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. *Cancer science*. 2009; 100:934–939. [PubMed: 19245434]

93. Li R, Song Y, Chen W. Enhancing radiosensitivity of human pulmonary adenocarcinoma cell line A549 by CpG ODN1826. *Cancer biotherapy & radiopharmaceuticals*. 2011; 26:69–76. [PubMed: 21355778]
94. Li X, et al. CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-kappaB activation and NO production. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2012; 33:1607–1618. [PubMed: 22739939]
95. Mason KA, et al. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. *Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology*. 2006; 80:192–198. [PubMed: 16905212]
96. Mason KA, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2005; 11:361–369. [PubMed: 15671567]
97. Meng Y, et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. *International journal of cancer. Journal international du cancer*. 2005; 116:992–997. [PubMed: 15856470]
98. Zhang H, et al. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. *PloS one*. 2012; 7:e38111. [PubMed: 22666458]
99. Kim YH, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. *Blood*. 2012; 119:355–363. [PubMed: 22045986]
100. Cerkovnik P, Novakovic BJ, Stegel V, Novakovic S. Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. *BMC immunology*. 2010; 11:45. [PubMed: 20836870]
101. Milas L, et al. CpG oligodeoxynucleotide enhances tumor response to radiation. *Cancer Res*. 2004; 64:5074–5077. [PubMed: 15289307]
102. Li X, et al. TLR9-ERK-mTOR signaling is critical for autophagic cell death induced by CpG oligodeoxynucleotide 107 combined with irradiation in glioma cells. *Scientific reports*. 2016; 6:27104. [PubMed: 27251306]
103. Xing N, et al. CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells. *OncoTargets and therapy*. 2015; 8:1443–1449. [PubMed: 26109868]
104. Gao C, et al. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. *Cancer Res*. 2013; 73:7211–7221. [PubMed: 24154870]
105. Monjazebe AM, et al. Blocking Indoleamine 2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2016
106. Lemos H, et al. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. *Cancer Res*. 2016
107. Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. *Journal of leukocyte biology*. 1989; 45:29–34. [PubMed: 2463322]
108. Baban B, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. *Int Immunol*. 2005; 17:909–919. [PubMed: 15967784]
109. Goubau D, et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. *Nature*. 2014; 514:372–375. [PubMed: 25119032]
110. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. *Immunity*. 2013; 38:855–869. [PubMed: 23706667]
111. Ranoa DR, et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. *Oncotarget*. 2016

112. Widau RC, et al. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. *Proceedings of the National Academy of Sciences of the United States of America*. 2014; 111:E484–491. [PubMed: 24434553]
113. Sun Q, et al. The specific and essential role of MAVS in antiviral innate immune responses. *Immunity*. 2006; 24:633–642. [PubMed: 16713980]
114. Chin AI, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. *Cancer Res*. 2010; 70:2595–2603. [PubMed: 20233880]
115. Stowell NC, et al. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. *Respir Res*. 2009; 10:43. [PubMed: 19486528]
116. Ishii KJ, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. *Nature immunology*. 2006; 7:40–48. [PubMed: 16286919]
117. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature*. 2008; 455:674–678. [PubMed: 18724357]
118. Zhong B, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. *Immunity*. 2008; 29:538–550. [PubMed: 18818105]
119. Baird JR, et al. Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. *Cancer Res*. 2016; 76:50–61. [PubMed: 26567136]
120. Ishikawa H, Barber GN. The STING pathway and regulation of innate immune signaling in response to DNA pathogens. *Cellular and molecular life sciences: CMLS*. 2011; 68:1157–1165. [PubMed: 21161320]
121. Sauer JD, et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to *Listeria monocytogenes* and cyclic dinucleotides. *Infect Immun*. 2011; 79:688–694. [PubMed: 21098106]
122. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature*. 2009; 461:788–792. [PubMed: 19776740]
123. Abe T, et al. STING recognition of cytoplasmic DNA instigates cellular defense. *Mol Cell*. 2013; 50:5–15. [PubMed: 23478444]
124. Deng L, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity*. 2014; 41:843–852. [PubMed: 25517616]
125. Woo SR, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. *Immunity*. 2014; 41:830–842. [PubMed: 25517615]
126. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. *Cell Rep*. 2015; 11:1018–1030. [PubMed: 25959818]
127. Dubensky TW Jr, Kanne DB, Leong ML. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. *Therapeutic advances in vaccines*. 2013; 1:131–143. [PubMed: 24757520]
128. Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. *Science translational medicine*. 2015; 7:283ra252.
129. Prantner D, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. *J Biol Chem*. 2012; 287:39776–39788. [PubMed: 23027866]
130. Downey CM, Aghaei M, Schwendener RA, Jirik FR. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. *PloS one*. 2014; 9:e99988. [PubMed: 24940883]
131. Conlon J, et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. *Journal of immunology*. 2013; 190:5216–5225.
132. Sali TM, et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. *PLoS Pathog*. 2015; 11:e1005324. [PubMed: 26646986]

133. Seshadri M, Toth K. Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer. *Transl Oncol.* 2009; 2:121–127. [PubMed: 19701496]
134. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. *Radiation research.* 2001; 156:503–509. [PubMed: 11604063]
135. Wilson W, Li A, Cowan DM, Siim B. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. *International Journal of Radiation Oncology*Biophysics*Physics.* 1998; 42:905–908.
136. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. *Annu Rev Immunol.* 2014; 32:513–545. [PubMed: 24555472]
137. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. *Annu Rev Immunol.* 2005; 23:307–336. [PubMed: 15771573]
138. Siegal FP, et al. The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood. *Science.* 1999; 284:1835–1837. [PubMed: 10364556]
139. Cella M, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. *Nature medicine.* 1999; 5:919–923.
140. Huang L, et al. Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. *Journal of immunology.* 2013; 191:3509–3513.
141. Lemos H, et al. Activation of the STING adaptor attenuates experimental autoimmune encephalitis. *Journal of immunology.* 2014; 192:5571–5578.
142. Terawaki S, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. *Journal of immunology.* 2011; 186:2772–2779.
143. Weichselbaum RR, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. *Proceedings of the National Academy of Sciences.* 2008; 105:18490–18495.
144. Duarte CW, et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. *PloS one.* 2012; 7:e29653. [PubMed: 22242177]
145. Burnette BC, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. *Cancer Res.* 2011; 71:2488–2496. [PubMed: 21300764]
146. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. *Cancer immunology, immunotherapy: CII.* 2014; 63:259–271. [PubMed: 24357146]
147. Grob JJ, et al. Randomised trial of interferon α -2a as adjuvant therapy in resected primary melanoma thicker than 15 mm without clinically detectable node metastases. *The Lancet.* 1998; 351:1905–1910.
148. Eggermont AMM, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. *The Lancet.* 2005; 366:1189–1196.
149. Wheatley K, et al. Does adjuvant interferon- α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. *Cancer Treatment Reviews.* 2003; 29:241–252. [PubMed: 12927565]
150. Dritschilo A, Mossman K, Gray M, Sreevalsan T. Potentiation of radiation injury by interferon. *American journal of clinical oncology.* 1982; 5:79–82. [PubMed: 6177232]
151. Zhu Y, Tibensky I, Schmidt J, Ryschich E, Marten A. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. *Journal of Immunotherapy.* 2008; 31:599–606. [PubMed: 18600184]
152. Zhu Y, et al. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. *Journal of Immunotherapy.* 2008; 31:28–33. [PubMed: 18157009]

153. Linehan DC, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. *Annals of surgery*. 2008; 248:145–151. [PubMed: 18650621]
154. Picozzi VJ, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. *Annals of oncology: official journal of the European Society for Medical Oncology/ESMO*. 2011; 22:348–354.
155. Schmidt J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2012; 30:4077–4083. [PubMed: 23008325]
156. Spaapen RM, et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. *Journal of immunology*. 2014; 193:4254–4260.
157. Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. *Blood*. 2010; 115:2864–2871. [PubMed: 20139095]
158. Yang X, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. *Cancer cell*. 2014; 25:37–48. [PubMed: 24434209]
159. Carswell EA, et al. An endotoxin-induced serum factor that causes necrosis of tumors. *Proceedings of the National Academy of Sciences*. 1975; 72:3666–3670.
160. Pennica D, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. *Nature*. 1984; 312:724–729. [PubMed: 6392892]
161. Vicari AP, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. *The Journal of experimental medicine*. 2002; 196:541–549. [PubMed: 12186845]
162. North RJ, Dunn PL, Havell EA. A role for tumor necrosis factor in poly(I:C)-induced hemorrhagic necrosis and T-cell-dependent regression of a murine sarcoma. *Journal of interferon research*. 1991; 11:333–340. [PubMed: 1839310]
163. Meng Y, et al. *Cancer research*. 2010; 70:1534–1543. [PubMed: 20145121]
164. Sparwasser T, et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock. *European Journal of Immunology*. 1997; 27:1671–1679. [PubMed: 9247576]
165. Dinarello CA. Proinflammatory and Anti-inflammatory Cytokines as Mediators in the Pathogenesis of Septic Shock. *Chest*. 1997; 112:321S–329S. [PubMed: 9400897]
166. Campbell JD, et al. CpG-containing immunostimulatory DNA sequences elicit TNF- α -dependent toxicity in rodents but not in humans. *The Journal of clinical investigation*. 2009; 119:2564–2576. [PubMed: 19726873]
167. Weichselbaum RR, Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. *Cancer Gene Ther*. 2009
168. Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. *Gene Ther*. 2002; 9:1396–1402. [PubMed: 12365005]
169. Mauceri HJ, et al. Tumor Necrosis Factor α (TNF- α) Gene Therapy Targeted by Ionizing Radiation Selectively Damages Tumor Vasculature. *Cancer research*. 1996; 56:4311–4314. [PubMed: 8813113]
170. Jung M, Dimtchev A, Velena A, Dritschilo A. Combining radiation therapy with interstitial radiation-inducible TNF- α expression for locoregional cancer treatment. *Cancer Gene Ther*. 2011; 18:189–195. [PubMed: 21052099]
171. Meng Y, et al. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8 $^{+}$ T cells. *Mol Ther*. 2010; 18:912–920. [PubMed: 20197756]
172. Herman JM, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2013; 31:886–894. [PubMed: 23341531]

173. Sckisel GD, et al. Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. *Immunity*. 2015; 43:240–250. [PubMed: 26231116]
174. Young KH, et al. Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. *PloS one*. 2016; 11:e0157164. [PubMed: 27281029]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Distribution of innate receptors across cell types in the ImmGen dataset
The graph shows gene expression of innate receptors in sorted cell types clustered into broad immune populations. Expression of each gene is normalized across cell populations and color-coded according to the key. There is significant variation in expression of innate sensors across immune cells. While receptors such as TLR4 are most highly expressed by macrophages and neutrophils, TLR9 shows extended expression into dendritic cells and B cells. Broadly, T cells exhibit low expression of TLR. By contrast, the innate sensor STING and the type I IFN receptor are very evenly expressed across many cell populations. This analysis is a result of data assembled by the ImmGen Consortium. Full analysis of gene expression patterns can be visualized at www.immgen.org.

Figure 2. Effect of adjuvant on immune cell relationships in the tumor and draining lymph nodes

In the absence of adjuvant, cell death mediated by radiation therapy drives M2 responses that suppress DC maturation and effector T cell function. Innate immune adjuvants can drive proinflammatory M1 responses, enhance DC cross presentation of tumor antigens to T cells in the lymph node in a supportive cytokine environment, and support effector T cell control of residual disease.